Consensus recommendations for the prophylaxis of venous thrombosis after total joint replacement (TEP) of the hip or knee
Abstract
Since 2009 are available in the new CR Antithrombotics - direct factor Xa inhibitor rivaroxaban and direct thrombin inhibitor dabigatran was for clinical use in the CR developed new recommendations for the extension of TE prophylaxis after elective orthopedic surgery hip and knee-known consensus recommendations for prophylaxis of venous thrombosis after total joint replacement of the hip or knee joint, including the addition to the use antithrombotics - UFH, LMWH, fondaparinux, and warfarin and both these new products.